Fresenius Kabi expands its critical care portfolio in the U.S.

Fresenius Kabi expands its portfolio of critical care medicine by launching Lacosamide Injection, USP, a generic equivalent to VIMPAT® in the U.S. 

Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in the U.S. beginning today. 

* VIMPAT® is a registered trademark of UCB, Inc.